Year: 2023

Interim, first-in-human clinical results from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b study of WTX-124 including safety and preliminary antitumor activity to be described in poster presentation. Additional posters representing an expansive body of data demonstrating the potential of Werewolf’s PREDATOR™ platform and INDUKINE™ product candidates will also be presented. Company to host conference call and webcast to review WTX-124 initial clinical results November 3, 2023, at 8:30 am ETWATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer,...

Novel, proprietary technology designed to strengthen the functionality of CAR-T cells against solid tumors SMART CAR-T cells demonstrated resistance to immunosuppressive tumor microenvironment (TME) and maintained long-term proliferation and cytotoxicity both in vitro and in vivo Launching investigator-initiated trial (IIT) of SMART CART GC506 targeting Claudin 18.2 positive tumors SAN DIEGO and SUZHOU, China and SHANGHAI, China, Oct. 31, 2023 (GLOBE NEWSWIRE) — Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, announced today preclinical data from the Company’s SMART CART™* technology for solid tumors will be presented as a...

SAN DIEGO, Oct. 31, 2023 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that financial advisor Carmen Pontelandolfo has joined LPL’s employee advisor channel, Linsco by LPL Financial, to launch CJP Wealth Management of LPL Financial. He reported having served approximately $135 million in advisory, brokerage and retirement plan assets* and joins LPL from Morgan Stanley. Based in his hometown of Marlton, N.J., Pontelandolfo is a seasoned financial professional with over three decades of industry experience. He was inspired to become an advisor after the 1987 Stock Market crash, choosing a profession that combines his interest in economics with his passion for relationship building and helping others. Pontelandolfo is joined by Client Services Associate Dana Debardeladen, who shares his core values and mission to treat clients...

Recently rebranded Scinai Immunotherapeutics shifted drug development focus from COVID-19 antibody to a novel antibody for the treatment of psoriasis and launched a CDMO business unit Adjusted terms being considered by EIB would extend maturity of finance facility and improve shareholders’ equityJERUSALEM, Oct. 31, 2023 (GLOBE NEWSWIRE) — via IBN — Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announced that its primary  creditor, the European Investment Bank (EIB), is currently considering favorably adjusting the terms of the EIB’s financial facility contract with the Company, in particular by...

Spatial Biology 2.0 solutions enable discovery and translational workflows at an unprecedented speed and scale Global network of CROs providing Akoya’s spatial phenotyping solutions will also exhibit at SITC MARLBOROUGH, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) — Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company®, today announced that it will be showcasing its latest Spatial Biology 2.0 solutions and ultrahigh-plex (100+ protein biomarkers) spatial phenotyping data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, being held in San Diego, California, November 1-5, 2023. At booth #719, Akoya Biosciences will highlight its new PhenoCycler®-Fusion 2.0 and PhenoImager® HT 2.0 platforms, which offer significant advancements in speed and scale for spatial biology research.PhenoCycler-Fusion 2.0: Features...

ROMEOVILLE, Ill., Oct. 31, 2023 (GLOBE NEWSWIRE) — Solésence Beauty Science, a leader in inclusive, mineral-based beauty products for skincare and makeup brands, and a wholly owned subsidiary of Nanophase Technologies Corporation, today announced that it has been named the winner of the 2023 BeautyMatter NEXT Award in the Best Contract Manufacturing category. This category recognizes companies that provide services related to the production, formulation, and filling of beauty and wellness products. We are excited to be receiving this award and to be recognized for our mission to bring life-changing skin health products to everyone. The BeautyMatter NEXT Awards aim to raise the bar and define the future of beauty. Solésence was selected from 400+ entries for over 50 awards across 7 categories. “Not only has Solésence Beauty Science...

Quincy, MA, Oct. 31, 2023 (GLOBE NEWSWIRE) — Stran & Company, Inc. (“Stran” or the “Company”) (NASDAQ: SWAG) (NASDAQ: SWAGW), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, today announced it will host a conference call at 10:00 A.M. Eastern Time on Monday, November 6, 2023, to discuss the Company’s financial results for the third quarter of 2023 ended September 30, 2023, as well as the Company’s corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and using entry code: 926511. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2855/49360 or on the Investor Relations...

Not for distribution to U.S. newswire services or for dissemination in the United States. TORONTO, Oct. 31, 2023 (GLOBE NEWSWIRE) — (TSX: LBS, LBS.PR.A) Life & Banc Split Banc Corp. (the “Company”) is pleased to announce that it has completed the previously announced treasury offering of preferred shares (“Preferred Shares”) for aggregate gross proceeds of approximately $94 million. The Preferred Shares will trade on the Toronto Stock Exchange (“TSX”) under the existing symbol LBS.PR.A. The Preferred Shares were offered at a price of $9.60 per Preferred Share for a yield to maturity of 8.3%.(1) The syndicate of agents for the offering was led by RBC Capital Markets, CIBC Capital Markets, National Bank Financial Inc., and Scotiabank and included Hampton Securities Limited, Canaccord Genuity Corp., BMO Capital Markets, Raymond...

ST. LOUIS, Oct. 31, 2023 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients in the United States have been treated successfully utilizing Abbott’s EnSite™ X EP System integrated with Stereotaxis’ Robotic Magnetic Navigation System. The integration of Abbott’s leading cardiac mapping system and Stereotaxis’ advanced robotic technology, first announced at Heart Rhythm 2023, combines highly detailed real-time diagnostic information with the unprecedented precision and stability of robotics during therapy delivery. The first integrated procedures in the US were completed by physicians at Weill Cornell Medical Center, Mount Sinai Morningside, Banner University Medical Center Phoenix, and Overland Park...

CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its third quarter 2023 financial results will be released on Tuesday, November 7, 2023 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of the company’s...